Skip to main content
Erschienen in:

10.08.2024 | Thoracic Oncology

Peritoneal Dissemination in Patients with Recurrence After Post-pleurectomy/decortication for Pleural Mesothelioma

verfasst von: Akifumi Nakamura, MD, PhD, Masaki Hashimoto, MD, PhD, Ayumi Kuroda, MD, PhD, Kyoshiro Takegahara, MD, PhD, Akihiro Fukuda, MD, Seiji Matsumoto, MD, PhD, Nobuyuki Kondo, MD, PhD, Toshiyuki Minami, MD, PhD, Kazuhiro Kitajima, MD, PhD, Kozo Kuribayashi, MD, PhD, Takashi Kijima, MD, PhD, Soichiro Funaki, MD, PhD, Seiki Hasegawa, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

In clinical practice, peritoneal dissemination after curative-intent surgery for pleural mesothelioma occasionally recurs. This study investigated the risk factors and prognosis associated with post-pleurectomy/decortication peritoneal dissemination in pleural mesothelioma, which are rarely reported.

Methods

This retrospective review included 160 patients who experienced recurrence after pleurectomy/decortication for pleural mesothelioma between January 2011 and December 2021. Patients with recurrence were classified according to the initial recurrence pattern. The P group experienced recurrence with peritoneal dissemination, and the non-P group experienced recurrence without peritoneal dissemination. The analysis determined the risk factors for peritoneal dissemination using multivariable logistic regression analysis. Survival was analyzed using the Kaplan–Meier method and the log-rank test.

Results

Of the 160 patients, 20 (12.5%) exhibited peritoneal dissemination and were assigned to the P group, whereas 140 (87.5%) had recurrence without peritoneal dissemination and were assigned to the non-P group. Multivariable logistic regression analysis showed that diaphragm reconstruction (odds ratio [OR], 2.8; 95% confidence interval [CI], 1.0–8.0; p = 0.048) and female sex (OR, 3.7; 95% CI 1.26–10.8; p = 0.017) were associated with the P group. Post-recurrence survival was worse in the P group than in the non-P group (1-year post-recurrence survival: 22.2% vs. 65.3%; median: 6.7 months vs. 19.4 months; p = 0.0013).

Conclusions

Peritoneal dissemination occurred in approximately one of every eight patients with recurrence after pleurectomy/decortication for pleural mesothelioma, and the incidence was significantly higher among females and patients undergoing diaphragm reconstruction. Moreover, postoperative recurrence of peritoneal dissemination was associated with a poor prognosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Burt BM, Lee HS, Lenge De Rosen V, et al. Soluble mesothelin-related peptides to monitor recurrence after resection of pleural mesothelioma. Ann Thorac Surg. 2017;104:1679–87.CrossRefPubMed Burt BM, Lee HS, Lenge De Rosen V, et al. Soluble mesothelin-related peptides to monitor recurrence after resection of pleural mesothelioma. Ann Thorac Surg. 2017;104:1679–87.CrossRefPubMed
2.
Zurück zum Zitat Nakamura A, Hashimoto M, Kuroda A, et al. Impact of operation on disease progression and survival of patients with pleural mesothelioma. Ann Thorac Surg. 2024;118:216–23.CrossRefPubMed Nakamura A, Hashimoto M, Kuroda A, et al. Impact of operation on disease progression and survival of patients with pleural mesothelioma. Ann Thorac Surg. 2024;118:216–23.CrossRefPubMed
3.
Zurück zum Zitat Nakamura A, Takuwa T, Hashimoto M, et al. Clinical outcomes with recurrence after pleurectomy/decortication for malignant pleural mesothelioma. Ann Thorac Surg. 2020;109:1537–43.CrossRefPubMed Nakamura A, Takuwa T, Hashimoto M, et al. Clinical outcomes with recurrence after pleurectomy/decortication for malignant pleural mesothelioma. Ann Thorac Surg. 2020;109:1537–43.CrossRefPubMed
4.
Zurück zum Zitat Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity, and survival after extra-pleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8:238–45.CrossRefPubMedPubMedCentral Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity, and survival after extra-pleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8:238–45.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Kostron A, Friess M, Crameri O, et al. Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016;49:1516–23.CrossRefPubMed Kostron A, Friess M, Crameri O, et al. Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016;49:1516–23.CrossRefPubMed
6.
Zurück zum Zitat Collins DC, Sundar R, Constantinidou A, et al. Radiological evaluation of malignant pleural mesothelioma: defining distant metastatic disease. BMC Cancer. 2020;20:1210.CrossRefPubMedPubMedCentral Collins DC, Sundar R, Constantinidou A, et al. Radiological evaluation of malignant pleural mesothelioma: defining distant metastatic disease. BMC Cancer. 2020;20:1210.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Nakamura A, Hashimoto M, Matsumoto S, Kondo N, Kijima T, Hasegawa S. Outcomes of conversion to extra-pleural pneumonectomy from pleurectomy/decortication for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2021;33:873–81.CrossRefPubMed Nakamura A, Hashimoto M, Matsumoto S, Kondo N, Kijima T, Hasegawa S. Outcomes of conversion to extra-pleural pneumonectomy from pleurectomy/decortication for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2021;33:873–81.CrossRefPubMed
8.
Zurück zum Zitat Nakamura A, Kondo N, Nakamichi T, et al. Complications and predictive factors for air leak > 10 days with neoadjuvant chemotherapy followed by pleurectomy/decortication for malignant pleural mesothelioma. Ann Surg Oncol. 2021;28:3057–65.CrossRefPubMed Nakamura A, Kondo N, Nakamichi T, et al. Complications and predictive factors for air leak > 10 days with neoadjuvant chemotherapy followed by pleurectomy/decortication for malignant pleural mesothelioma. Ann Surg Oncol. 2021;28:3057–65.CrossRefPubMed
9.
Zurück zum Zitat Nakamura A, Hashimoto M, Kondo N, et al. Long-term outcomes and risk factors of residual thoracic spaces after pleurectomy/decortication for mesothelioma. Eur J Cardiothorac Surg. 2022;63:ezac500.CrossRefPubMed Nakamura A, Hashimoto M, Kondo N, et al. Long-term outcomes and risk factors of residual thoracic spaces after pleurectomy/decortication for mesothelioma. Eur J Cardiothorac Surg. 2022;63:ezac500.CrossRefPubMed
10.
Zurück zum Zitat Hasegawa S, Kondo N, Matsumoto S, et al. Surgical risk and survival associated with less invasive surgery for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2019;31:301–9.CrossRefPubMed Hasegawa S, Kondo N, Matsumoto S, et al. Surgical risk and survival associated with less invasive surgery for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2019;31:301–9.CrossRefPubMed
11.
Zurück zum Zitat Friedberg JS, Culligan MJ, Tsao AS, et al. A proposed system toward standardizing surgical-based treatments for malignant pleural mesothelioma, from the joint National Cancer Institute–international association for the study of lung cancer-mesothelioma applied research foundation taskforce. J Thorac Oncol. 2019;14:1343–53.CrossRefPubMed Friedberg JS, Culligan MJ, Tsao AS, et al. A proposed system toward standardizing surgical-based treatments for malignant pleural mesothelioma, from the joint National Cancer Institute–international association for the study of lung cancer-mesothelioma applied research foundation taskforce. J Thorac Oncol. 2019;14:1343–53.CrossRefPubMed
12.
Zurück zum Zitat Sharkey AJ, Tenconi S, Nakas A, Waller DA. The effects of an intentional transition from extra-pleural pneumonectomy to extended pleurectomy/decortication. Eur J Cardiothorac Surg. 2016;49:1632–41.CrossRefPubMed Sharkey AJ, Tenconi S, Nakas A, Waller DA. The effects of an intentional transition from extra-pleural pneumonectomy to extended pleurectomy/decortication. Eur J Cardiothorac Surg. 2016;49:1632–41.CrossRefPubMed
13.
Zurück zum Zitat Ambrogi MC, Bertoglio P, Aprile V, et al. Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: a 10-year experience. J Thorac Cardiovasc Surg. 2018;155:1857-1866.e2.CrossRefPubMed Ambrogi MC, Bertoglio P, Aprile V, et al. Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: a 10-year experience. J Thorac Cardiovasc Surg. 2018;155:1857-1866.e2.CrossRefPubMed
14.
Zurück zum Zitat Lee M, Ventura L, Baranowski R, Hargrave J, Waller D. The effects of preserving the diaphragm on early and late outcome of lung-sparing radical surgery for malignant pleural mesothelioma. J Clin Med. 2022;11:6839.CrossRefPubMedPubMedCentral Lee M, Ventura L, Baranowski R, Hargrave J, Waller D. The effects of preserving the diaphragm on early and late outcome of lung-sparing radical surgery for malignant pleural mesothelioma. J Clin Med. 2022;11:6839.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Oguri M, Okanishi T, Ikeguchi T, et al. Influence of gender on diaphragm thickness using a method for determining intima media thickness in healthy young adults. BMC Med Imaging. 2022;22:26.CrossRefPubMedPubMedCentral Oguri M, Okanishi T, Ikeguchi T, et al. Influence of gender on diaphragm thickness using a method for determining intima media thickness in healthy young adults. BMC Med Imaging. 2022;22:26.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Takuwa T, Hashimoto M, Matsumoto S, et al. Post-recurrence chemotherapy for mesothelioma patients undergoing extra-pleural pneumonectomy. Int J Clin Oncol. 2017;22:857–64.CrossRefPubMed Takuwa T, Hashimoto M, Matsumoto S, et al. Post-recurrence chemotherapy for mesothelioma patients undergoing extra-pleural pneumonectomy. Int J Clin Oncol. 2017;22:857–64.CrossRefPubMed
17.
Zurück zum Zitat Nakamura A, Takuwa T, Hashimoto M, et al. Radiofrequency ablation effectively treated focal recurrence of mesothelioma. Ann Thorac Surg. 2018;105:e265–7.CrossRefPubMed Nakamura A, Takuwa T, Hashimoto M, et al. Radiofrequency ablation effectively treated focal recurrence of mesothelioma. Ann Thorac Surg. 2018;105:e265–7.CrossRefPubMed
18.
Zurück zum Zitat Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375–86.CrossRefPubMed Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375–86.CrossRefPubMed
19.
Zurück zum Zitat Dumoulin DW, Douma LH, Hofman MM, et al. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma. Lung Cancer. 2024;187:107440.CrossRefPubMed Dumoulin DW, Douma LH, Hofman MM, et al. Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma. Lung Cancer. 2024;187:107440.CrossRefPubMed
20.
Zurück zum Zitat Nakamura A, Hashimoto M, Kondo N, et al. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention. Int J Clin Oncol. 2023;28:409–15.CrossRefPubMed Nakamura A, Hashimoto M, Kondo N, et al. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention. Int J Clin Oncol. 2023;28:409–15.CrossRefPubMed
21.
Zurück zum Zitat Bölükbas S, Eberlein M, Schirren J. Recurrence of malignant pleural mesothelioma at the resection borders–local or distant recurrence? J Thorac Oncol. 2013;8:e65.CrossRefPubMed Bölükbas S, Eberlein M, Schirren J. Recurrence of malignant pleural mesothelioma at the resection borders–local or distant recurrence? J Thorac Oncol. 2013;8:e65.CrossRefPubMed
Metadaten
Titel
Peritoneal Dissemination in Patients with Recurrence After Post-pleurectomy/decortication for Pleural Mesothelioma
verfasst von
Akifumi Nakamura, MD, PhD
Masaki Hashimoto, MD, PhD
Ayumi Kuroda, MD, PhD
Kyoshiro Takegahara, MD, PhD
Akihiro Fukuda, MD
Seiji Matsumoto, MD, PhD
Nobuyuki Kondo, MD, PhD
Toshiyuki Minami, MD, PhD
Kazuhiro Kitajima, MD, PhD
Kozo Kuribayashi, MD, PhD
Takashi Kijima, MD, PhD
Soichiro Funaki, MD, PhD
Seiki Hasegawa, MD, PhD
Publikationsdatum
10.08.2024
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-15984-5

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

Bisher wird für den interventionellen Mitralklappenersatz standardmäßig der transapikale Zugangsweg gewählt. In einer Registeranalyse hat dieser in puncto Sicherheit allerdings den Kürzeren gezogen.

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Appendektomie erhält Remission bei Colitis ulcerosa

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.